Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLINN: N-803 + Ipilimumab + Nivolumab in Stage IV/Recurrent NSCLC
NCT07355205Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2026
- Primary completion
- Jul 2032
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept in non-small cell lung cancer (NSCLC), sponsored by Washington University School of Medicine. Started Jul 2026; status: recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07355205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07355205.